Exploit Oncolytic Viruses through Optimized Pre-Clinical Translation,
Improved Delivery Beyond IV Carrier Cells & Enhanced Clinical Grade Manufacturing to Successfully, Selectively & Effectively Eliminate Cancer

Welcome to the 8th Oncolytic Virotherapy Summit: Engineering Oncolytic Viruses Towards Revolutionary Anti-Cancer Immunotherapies

Recent years have seen highly promising and rapid advances in the pre-clinical development and clinical evolution of oncolytic virotherapies. They are increasingly being recognised as a therapy with huge potential to change the landscape for cancer immunotherapy. In the past 3 months alone, we have witnessed 20 new drugs entering into pre-clinical and clinical phases, and exciting FDA Fast Track Designation for Candel Therapeutics OV candidate – this community continues to maximize the impact of these hopeful therapies.

Expert Speaker Faculty Includes:

Angelica Loskog

Chief Executive Officer

Lokon Pharma AB

Boris Minev

Interim Chief Medical Officer & President, Medical and Scientific Affairs

Calidi Biotherapeutics Inc.

Francesca Barone


Candel Therapeutics

Johanna Kaufmann

Executive Vice President, Oncology and Immunology

Codagenix, Inc.

Michael Franti

Director & Head of Regenerative Medicine, Viral Platform, Drug Metabolism & Pharmacokinetics

Boehringer Ingelheim

Paul Hallenbeck

Founder, President & Chief Executive & Scientific Officer

Seneca Therapeutics Inc.

Praveen Bommareddy

Senior Director - Translational Research


Richard Dambra

Viral Platforms, Drug Metabolism & Pharmacokinetics Scientist

Boehringer Ingelheim RCV GmbH & Co KG

Stephen Thorne


KaliVir Immunotherapeutics

Talia Biran

President, Oncolys USA

Oncolys BioPharma Inc.

Unite with 100+ OV trailblazers across sessions spanning Early Discovery, Translation, Clinical Development, Chemistry, Manufacturing & Controls (CMC) and Regulations to overcome the industry’s largest and critical bottlenecks. Meet your community to hear how they address the major challenges facing the industry:

Investigate the Manufacturing Challenges & Approaches to Produce a Successful Oncolytic Virus to Ensure its Quality, Traceability, & Reliability
Understand the raw materials and supply chain management of your oncolytic virus and, explore the importance of stability of your viral vectors with insights from VYRIAD & Circio Bio
Optimize the Immunogenicity of Your Oncolytic Virus Candidate: Maximizing Effectiveness & Minimizing Side Effects in Cancer Treatment
Discuss the current immunogenicity studies to support FIM studies and assess the safety and efficacy of your oncolytic virus with insights from Boehringer Ingelheim & Omios Biologics
Review How to Bridge the Gap Between Pharma, Biotech & Investors to Facilitate the Growth & Development of This Field
Address the importance of collaboration and investment in advancing pharma and biotech innovations, and discuss the strategies for mitigating risks and maximizing returns on investment with insights from Candel Therapeutics & Valo Therapeutics 
Discover the Potential of Using Combination Therapy for Improved Therapeutic Outcomes
Investigate the innovative combinations of oncolytic viruses with other therapeutic modalities as well as review the current pre-clinical and clinical studies demonstrating anti-tumor efficacy with insights from Replimune & Oncolys
Explore the Latest Clinical Data & How to Design Better Clinical Trials to Develop More Effective Oncolytic Virus’s
Discussing the most up to date clinical data on advancements in oncolytic viruses and what are the possible breakthroughs and innovations we may see in the next year with insights from Lokon Pharma & Calidi Therapeutics

Past Attendees Include:

Amgen Logo
Astellas Logo
BMS Logo
Boehringer Ingelheim Logo
Calidi Logo
CG Oncology Logo
Seneca Logo
tilt Logo
transgene Logo